Cancer

Texas Has Given Birth to Its First and Only Global Publicly Traded Cannabis Company, Cannabis Bioscience International Holdings

This Calls for a CelebrationHouston, Texas--(Newsfile Corp. - December 15, 2023) - On December 5, 2023, Cannabis Bioscience International Holdings…

11 months ago

Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at Stanford Medicine

- Stanford Medicine, a center with a long tradition of leadership in pioneering gynecological research and innovation, is the second…

11 months ago

Zymeworks Added to Nasdaq Biotechnology Index

VANCOUVER, British Columbia, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional…

11 months ago

CorMedix Inc. Announces Appointment of Chief Legal Officer

BERKELEY HEIGHTS, N.J., Dec. 15, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and…

11 months ago

Carrick Therapeutics Announces First Patient Dosed in Phase 2b Clinical Trial of Samuraciclib in Combination with Fulvestrant in Patients with Advanced HR+, HER2- Breast Cancer

BOSTON, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, today…

11 months ago

Check-Cap Board of Directors Issues Letter to Shareholders

ISFIYA, Israel, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Check-Cap, Ltd. (the “Company” or “Check-Cap”) (NASDAQ: CHEK) today issued the following…

11 months ago

Neoleukin Therapeutics Announces 1-for-4 Reverse Stock Split

SEATTLE, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” or the “Company” (NASDAQ:NLTX), a biopharmaceutical company that has…

11 months ago

Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines

CAMBRIDGE, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic, targeted oncology…

11 months ago

Precipio Management Shares Thoughts on 2023, and Looks Ahead To 2024

NEW HAVEN, Conn., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Management of specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) shares thoughts…

11 months ago